Related Experiment Video

Updated: Jun 6, 2026

Assessment of Mitochondrial Health in Cancer-Associated Fibroblasts Isolated from 3D Multicellular Lung Tumor Spheroids
10:26

Assessment of Mitochondrial Health in Cancer-Associated Fibroblasts Isolated from 3D Multicellular Lung Tumor Spheroids

Published on: October 21, 2022

TRX is up-regulated by fibroblast growth factor-2 in lung carcinoma

Zheng-Hao Deng1, Hui-Qiu Cao, Yong-Bin Hu

  • 1Department of Pathology, XiangYa School of Medicine, Central South University, Changsha, Hunan Province, China.

APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
|December 15, 2010
PubMed

Insights

Fibroblast growth factor-2 (FGF-2) inhibits small-cell lung cancer (SCLC) cell death. This study identifies thioredoxin (TRX) as a key protein upregulated by FGF-2, suggesting its role in SCLC progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Exogenous fibroblast growth factor-2 (FGF-2) inhibits apoptosis in small-cell lung cancer (SCLC) cells.
  • The precise molecular mechanisms underlying FGF-2's anti-apoptotic effects in SCLC are not fully understood.

Purpose of the Study:

  • To elucidate the protein expression changes in NCI-H446 SCLC cells upon FGF-2 treatment.
  • To identify specific proteins involved in the FGF-2 signaling pathway that may contribute to SCLC cell survival.

Main Methods:

  • Proteomic analysis using 2-D gel electrophoresis and MALDI-TOF-MS to compare FGF-2-treated and untreated NCI-H446 cells.
  • Bioinformatics analysis to identify differentially expressed proteins.
  • Western blotting and immunohistochemical staining to validate protein expression and localization in cell lines and clinical tissues.

Main Results:

  • FGF-2 treatment resulted in differential expression of 24 protein spots, with 9 up-regulated and 15 down-regulated.
  • Key identified proteins included thioredoxin (TRX), visfatin, UCHL1, and CuZn-SOD.
  • TRX was confirmed to be up-regulated by FGF-2 in NCI-H446 and A549 cells.
  • FGF-2 and TRX were overexpressed in lung cancer tissues and correlated with lymph node metastasis and clinical stage.

Conclusions:

  • Thioredoxin (TRX) is significantly up-regulated by FGF-2 in SCLC cells.
  • TRX overexpression in lung cancer tissues suggests a potential role in tumor progression and links it to the FGF-2 signaling pathway.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...